Systemic Lupus Erythematosus Market is segmented By Drug Class (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs, Cytotoxic, and Immunosuppressive Drugs, Biologics, Others), By Mode of Delivery (Intravenous, Sub-cutaneous, Oral, Topical), By Distribution Channel (Retail Pharmacies, Hospitals, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
Global Systemic Lupus Erythematosus market to grow at a CAGR Of 7.3% during the forecast period 2024-2031. The competitive rivalry intensifies with Anthera Pharmaceuticals, Eli Lilly., Sanofi, and others operating in the market.
In this disease, the immune system attacks its own tissues, thereby proliferating and causing inflammation to other organs of body. The condition tends to affect more women, and between the ages of 25 and 45 is when it often first manifests. Due to an increase in the disease's prevalence, rising public awareness of the illness, and the introduction of new medications, the global systemic lupus erythematosus market is expected to have a boost over the forecast period.
Market Summary
| Metrics | Details |
| CAGR | 7.3% |
| Size Available for Years | 2022-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$) |
| Segments Covered | Drug Class, Mode of Delivery, Distribution Channel, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more insights Download Sample
Market Dynamics
Advancements in the Diagnosis and Treatments of Disease Will Drive the Global Systemic Lupus Erythematosus (SLE) Market Growth
The development of more precise diagnostic procedures is a result of improvements in SLE diagnosis. SLE can be difficult to diagnose since its symptoms can vary and be vague, making it difficult to distinguish it from other autoimmune disorders. Nevertheless, improvements in laboratory testing have made it simpler to identify and treat SLE. For instance, new biomarkers are being discovered that can aid in the early diagnosis and tracking of disease activity, and antinuclear antibody (ANA) tests have improved in sensitivity.
Biologics are gaining popularity over the other drugs such as immusupressant, and corticosteriods, for instance, Benlysta a monoclonal antibody which inhibits the B-cells is approved biologic for SLE. Therefore, new developments and establishments for treating SLE, will drive the global systemic lupus erythematosus market over the forecast period.
The Adoption Towards Digital Health Technologies Will Create Lucrative Global Systemic Lupus Erythematosus Market Opportunities
Digital health technology, such as telemedicine, can enhance patient outcomes, boost patient involvement, and save healthcare costs. Telemedicine can be utilised to offer virtual consultations and follow-up care for SLE patients, enabling them to obtain treatment without having to physically visit a hospital. It is helpful for patients with mobility challenges or those who reside in rural places.
Furthermore, telemedicine can be useful in reducing the cost associated with the treatment of SLE, for example it can reduce the need for in-person visits, which can be costly for patients and healthcare providers. Therefore, digital health technologies can create a significant opportunity for global systemic lupus erythematosus market growth.
High Cost Associated With SLE Drugs Will Hamper The Market Growth
The high cost of SLE medicines is one of the main inhibitors for the global systemic lupus erythematosus (SLE) market. As SLE is a chronic autoimmune disease, it needs to be managed over the long term, and the expense of therapy may be a big burden on individuals and healthcare systems. Patients who are unable to pay for or obtain the required therapies experience poor results due to the high cost of SLE treatments, which can restrict access to therapy.
Market Segmentation Analysis
The global systemic lupus erythematosus market is segmented based on drug class, mode of delivery, distribution channel, and region.
The Antimalarial Drugs Segment is Expected to Dominate The Global Systemic Lupus Erythematosus Market.
The antimalarial drugs segment dominated the global systemic lupus erythematosus market and accounted the highest systemic lupus erythematosus market share of 29.8%. Systemic lupus erythematosus (SLE) patients frequently take anti-malarial medications, which are predicted to dominate the SLE market in the drug category sector. For mild to severe SLE, anti-malarial medications like hydroxychloroquine and chloroquine are frequently used as first-line therapy since they have been found to be successful in lowering disease activity and avoiding illness flares.
Particularly in SLE patients, hydroxychloroquine has been proven to be beneficial in lowering disease activity, relieving skin and joint symptoms, and lowering the risk of organ damage. Additionally, patients typically tolerate hydroxychloroquine well and it has a good safety profile and relatively low cost compared to other drug classes . Therefore, owing to the above factors, the antimalarial drug segment is likely to play major role in accelarating the global systemic lupus erythematosus market growth.
Source: DataM Intelligence Analysis (2023)
Market Geographical Share
North America Region Holds The Largest Market Share of the Global Systemic Lupus Erythematosus Market
North America is expected to hold a dominant position in the global systemic lupus erythematosus market clinching 1/3rd share of the total systemic lupus erythematosus market, owing to the factors such as the increased awareness of the condition, improved healthcare system, and increasing number of foundations and independent venture firms supporting the production of biopharmaceuticals.
For instance, according to Hospital for Special Surgery report, 500,000 people have been affected by SLE in the US. Therefore, owing to these factors, North America will dominate the global systemic lupus erythematosus market over the forecast period.
Source: DataM Intelligence Analysis (2023)
Market Companies
The major global players in the market include Anthera Pharmaceuticals Inc., Eli Lilly, GlaxoSmithKline, F. Hoffmann-La Roche, Pfizer, Sanofi, Lycera Corporation, Bristol-Myers Squibb, ImmuPharma Plc, and Merck KGaA
COVID-19 Impact on Systemic Lupus Erythematosus Market
Systemic lupus erythematosus (SLE) is a condition that has significantly affected the world market since the COVID-19 pandemic. Patient access to care has been one of the pandemic's significant effects. Due to the increased risk of developing a serious sickness from COVID-19 for many immunocompromised SLE patients, there has been a decline in the number of patients seeing doctors and hospitals. Delays in diagnosis and treatment have occurred as a result, which may have an adverse effect on patient outcomes.
The COVID-19 epidemic has not only hampered patient access to care but also the flow of SLE medicines via the supply chain. Due to the pandemic's effects on SLE medicine production, distribution, and supply, there are now shortages and higher expenses for patients and healthcare systems.
Russia Ukraine Conflict Analysis
The Russia-Ukraine conflict could potentially have indirect impacts on the global systemic lupus erythematosus (SLE) market, particularly with regards to the supply chain for SLE medications. Ukraine is one of the faster growing producer of pharmaceuticals and supplies many medications to other countries. The conflict could disrupt the supply chain for SLE medications if manufacturing facilities or transportation routes are damaged or closed.
It could also lead to a decrease in healthcare infrastructure and access to care in the region, which could result in delayed diagnosis and treatments for patients with SLE in Ukraine and surrounding areas. However, the global SLE market is diverse and not heavily reliant on any one region or country for the supply of medications.
Key Developments
- In March 2023, AbbVie announced the results of a Phase II study of upadacitinib (RINVOQ, 30 mg), a selective and reversible JAK inhibitor, given alone or in combination (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg), once daily in patients with moderate to severely active systemic lupus erythematosus (SLE).
- In August 2022, research from the Corporal Michael J. Creszcenz VAMC and the Perelman School of Medicine at the University of Pennsylvania, an experimental drug called litifilimab (also known as BIIB059) may be an effective long-term treatment for cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin and can have a significant negative impact on quality of life. The research medication was successful in reducing skin CLE activity.
- In May 2023, the U.S. Food and Drug Administration (FDA) has given CABA-201, an experimental therapy by Cabaletta Bio, Fast Track designation as a potential treatment for lupus and lupus nephritis (LN, lupus-related kidney illness).
The global systemic lupus erythematosus market report would provide approximately 53 tables, 54 figures, and 195 Pages.
